Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Pharmacy Benefit Managers (PBMs)
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Display Only
Showing 1216 Results
NPC’s Dr. Graff on Developing Evidence That Is “Fit for Purpose”
What information do payers feel they need to guide their coverage decisions? Jennifer Graff, PharmD, vice president of comparative effectiveness research at the National Pharmaceutical Council (NPC),…
NPC’s Dr. Dubois to Discuss Value Frameworks & Risk-Sharing at Pharmaceutical Summit
NPC Chief Science Officer Dr. Robert W. Dubois will present “Developing and Using Value-Based Frameworks for Pharmaceuticals and Guiding Standards for How to Implement Such Frameworks Correctly” and…
NPC Looks at ASCO's Updated Value Assessment Framework
While the American Society of Clinical Oncology's value assessment framework is still far from perfect, the organization should be commended for the steps it took to listen to outside stakeholders…
NPC’s Dr. Graff to Discuss What Value Should Look Like at BIO Convention
What should value look like? This is the question Jennifer Graff, PharmD, vice president of comparative effectiveness research at the National Pharmaceutical Council (NPC), and fellow panelists will…
CER Collaborative Offers New Tools and Training for New Challenges
Comparative effectiveness research (CER) can help decision-makers use evidence-based insights to improve health care and outcomes for patients. But do decision-makers have the tools and training they…
It’s Important to Have Many Voices in the Value Conversation
Value means different things to different stakeholders, which is why it’s good to see so many voices engaging in this important discussion. Value assessment has the potential to have a tremendous…
Got CER? Educating Pharmacists for Practice in the Future: New Tools for New Challenges
This study provides an early evaluation of the CER Collaborative's training program's impact on learners’ self-reported abilities to evaluate and incorporate comparative effectiveness research…
PQA’s Annual Meeting To Discuss Progress Toward Value-Based Goals
This year’s Pharmaceutical Quality Alliance’s Annual Meeting, which the National Pharmaceutical Council is cosponsoring, will gather leaders from all stakeholder communities to discuss the state of…
Budget Impact Analysis: An Acceptable Part of Value Assessments or a Discordant Concept?
Value assessments are an evolving area, yet growing in use as health care stakeholders look for ways to evaluate the value of care that is being provided to patients.
The Third Rail—Why Budget Impact Assessments are Not Measures of Value
The National Pharmaceutical Council’s "Guiding Practices for Patient-Centered Value Assessment" address one particular issue that could have significant unintended consequences: budget impact…
Harnessing Data for the Cancer Moonshot
When Vice President Joe Biden speaks at Health Datapalooza on May 9, it will be an exciting reminder of all of the possibilities that health care data holds in seeking cures for cancer and improving…
Tackling Data Access at Health Datapalooza
NPC is looking forward to a robust conversation at Health Datapalooza about how all stakeholders can access and harness the power of data.
Spreading the Word About a Value Assessment: Dissemination and Utilization Factors to Consider
The National Pharmaceutical Council recently unveiled Guiding Practices for Patient-Centered Value Assessment, which offer comprehensive considerations for the development and application of…
NPC Resources Provide Information on Panel Topics at 2016 Armada Specialty Summit
Will you be attending the 2016 Armada Specialty Pharmacy Summit in Las Vegas from May 2-6? Get prepared for the conversations and meetings on event topics with some helpful background resources,…
Don't Miss NPC at ISPOR's 21st Annual International Meeting!
NPC will host a pre-conference symposium, present on various pressing health policy topics and exhibit at the International Society for Pharmacoeconomics and Outcomes Research’s 21st Annual…
AMCP Outlines Changes to Format for Formulary Submissions
The Academy of Managed Care Pharmacy today released its updated Format for Formulary Submissions, Version 4.0, which enables health care decision-makers and biopharmaceutical companies to…
Bundled Payments: Opportunities and Challenges
A study by NPC Director of Research Michael Ciarametaro and Chief Science Officer Dr. Robert W. Dubois published on the Health Affairs blog lays out core principles that are critical to steering…
Designing Successful Bundled Payment Initiatives
The National Pharmaceutical Council led a study that identified three principles intended to maximize the positive aspects and minimize the negative consequences of bundled payments.
Using Evidence Appropriately to Inform Value Assessments
The National Pharmaceutical Council recently unveiled “Guiding Practices for Patient-Centered Value Assessment,” which offer comprehensive considerations for the development and application of…